Global Emergence of Resistance to Fluconazole and Voriconazole in Candida parapsilosis in Tertiary Hospitals in Spain During the C OVID-19 Pandemic
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Background: Candida parapsilosis is a frequent cause of candidemia worldwide. Its incidence is associated with the use of medical implants, such as central venous catheters or parenteral nutrition. This species has reduced susceptibility to echinocandins, and it is susceptible to polyenes and azoles. Multiple outbreaks caused by fluconazole-nonsusceptible strains have been reported recently. A similar trend has been observed among the C. parapsilosis isolates received in the last 2 years at the Spanish Mycology Reference Laboratory. Methods: Yeast were identified by molecular biology, and antifungal susceptibility testing was performed using the European Committee on Antimicrobial Susceptibility Testing protocol. The ERG11 gene was sequenced to identify resistance mechanisms, and strain typing was carried out by microsatellite analysis. Results: We examined the susceptibility profile of 1315 C. parapsilosis isolates available at our reference laboratory between 2000 and 2021, noticing an increase in the number of isolates with acquired resistance to fluconazole, and voriconazole has increased in at least 8 different Spanish hospitals in 2020–2021. From 121 recorded clones, 3 were identified as the most prevalent in Spain (clone 10 in Catalonia and clone 96 in Castilla-Leon and Madrid, whereas clone 67 was found in 2 geographically unrelated regions, Cantabria and the Balearic Islands). Conclusions: Our data suggest that concurrently with the coronavirus disease 2019 pandemic, a selection of fluconazole-resistant C. parapsilosis isolates has occurred in Spain, and the expansion of specific clones has been noted across centers. Further research is needed to determine the factors that underlie the successful expansion of these clones and their potential genetic relatedness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, fluconazole resistance has emerged over the last decade and over 50% of C. parapsilosis isolates are resistant in some series.64,119”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [119]
The cited source says what the claim attributes to it.
In the citing paper
“However, fluconazole resistance has emerged over the last decade and over 50% of C. parapsilosis isolates are resistant in some series.64,119”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PCR protocols — A guide to methods and applications
U.G. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90252-7 · Cited by 11,702
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Changes in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547
Bartoletti, M., Pascale, R., Cricca, M., Rinaldi, M., Maccaro, A., Bussini, L., Fornaro, G., Tonetti, T., Pizzilli, G., Francalanci, E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1065 · Cited by 473
Candida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327
Puig-Asensio, M., Padilla, B., Garnacho-Montero, J., Zaragoza, O., Aguado, J. M., Zaragoza, R., Montejo, M., Muñoz, P., Ruiz-Camps, I., Cuenca-Estrella, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12380 · Cited by 299 · cited 2×
“associated to a higher risk of infection [5, 6].”
BackgroundResultSelf-citationArastehfar, A., Carvalho, A., Nguyen, M. H., Hedayati, M. T., Netea, M. G., Perlin, D. S., & Hoenigl, M. (2020) · Journal of Fungi · doi:10.3390/jof6040211 · Cited by 272 · cited 1×
“diseases, such as COVID-associated pulmonary aspergillosis (CAPA) [36–38], mucormycosis [39–41], and Candida infections [42, 43] (see reviews in [44, 45]).”
BackgroundCOVID-19-associated opportunistic infections: a snapshot on the current reports
Abdoli, A., Falahi, S., & Kenarkoohi, A. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-021-00751-7 · Cited by 184 · cited 1×
“11 Pulmonary Aspergillosis (CAPA) [35-37], mucormycosis [38-40] and Candida 352 infections [41, 42] (see reviews in [43, 44]).”
BackgroundPeman, J., Canton, E., Quindos, G., Eraso, E., Alcoba, J., Guinea, J., Merino, P., Ruiz-Perez-de-Pipaon, M. T., Perez-del-Molino, L., Linares-Sicilia, M. J., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks019 · Cited by 159 · cited 1×
“the several former epidemiological studies that have been carried out in Spain 313 [6, 7, 30, 31], suggesting a new and worrisome change in the epidemiological 314 incidence of FNS C.”
ResultSelf-citationCantón, E., Pemán, J., Quindós, G., Eraso, E., Miranda-Zapico, I., Álvarez, M., Merino, P., Campos-Herrero, I., Marco, F., de la Pedrosa, E. G. G., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00466-11 · Cited by 157 · cited 1×
“the several former epidemiological studies that have been carried out in Spain 313 [6, 7, 30, 31], suggesting a new and worrisome change in the epidemiological 314 incidence of FNS C.”
ResultChong, W. H., & Neu, K. (2021) · Journal of Hospital Infection · doi:10.1016/j.jhin.2021.04.012 · Cited by 152 · cited 2×
“8 • OFID • Trevijano-Contador et al diseases, such as COVID-associated pulmonary aspergillosis (CAPA) [36–38], mucormycosis [39–41], and Candida infections [42, 43] (see reviews in [44, 45]).”
BackgroundGovender, N. P., Patel, J., Magobo, R. E., Naicker, S., Wadula, J., Whitelaw, A., Coovadia, Y., Kularatne, R., Govind, C., Lockhart, S. R., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw091 · Cited by 147 · cited 2×
“In 98 recent years, however, a steady increase of resistance has been observed 99 worldwide, mostly in the context of nosocomial outbreaks [11-20].”
BackgroundArendrup, M. C., Meletiadis, J., Mouton, J. W., Guinea, J., Cuenca‐Estrella, M., Lagrou, K., Howard, S. J., Arendrup, M. C., Meletiadis, J., Howard, S. J., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.01.017 · Cited by 145 · cited 1×
“135 Antifungal susceptibility 136 Antifungal susceptibility testing was performed following EUCAST protocol 137 (RPMI 1640 medium (Merck, Sigma-Aldrich) buffered with MOPS (Merck, 138 Sigma-Aldrich) at pH 7 and supplemented with 2% glucose (Merck, Sigma139 Aldrich), [24]).”
MethodSelf-citationThe Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030138 · Cited by 145 · cited 1×
“Another strain harbored the G458S mutation, which has also been related 245 to azole resistance in Candida parapsilosis [4, 28].”
BackgroundGuinea, J., Zaragoza, Ó., Escribano, P., Martín-Mazuelos, E., Pemán, J., Sánchez-Reus, F., & Cuenca-Estrella, M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02155-13 · Cited by 131
Self-citationThomaz, D. Y., de Almeida, J. N., Lima, G. M. E., Nunes, M. D. O., Camargo, C. H., Grenfell, R. D. C., Benard, G., & Del Negro, G. M. B. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02997 · Cited by 124 · cited 2×
“In 98 recent years, however, a steady increase of resistance has been observed 99 worldwide, mostly in the context of nosocomial outbreaks [11-20].”
BackgroundGrossman, N. T., Pham, C. D., Cleveland, A. A., & Lockhart, S. R. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04613-14 · Cited by 112 · cited 1×
“In many 100 cases, these outbreaks are monoclonal, and are associated to mutations in 101 ERG11 (mainly with the Y132F mutation), overexpression of efflux pumps (as 102 Mdr1 and Cdr1) and mutations in MRR1, which encodes a transcription factor 103 that regulates the expression of some efflux pumps [11-13, 16, 18, 21,…”
BackgroundArastehfar, A., Daneshnia, F., Hilmioğlu-Polat, S., Fang, W., Yaşar, M., Polat, F., Metin, D. Y., Rigole, P., Coenye, T., Ilkit, M., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01001-20 · Cited by 110 · cited 6×
“parapsilosis strains harboring 364 the Y132F mutation in ERG11 have reduced ability to form biofilms [11], which 365 rises the hypothesis that these strains have a higher ability to spread and 366 disseminate.”
BackgroundInfluentialThomaz, D. Y., de Almeida, J. N., Sejas, O. N. E., Del Negro, G. M. B., Carvalho, G. O. M. H., Gimenes, V. M. F., de Souza, M. E. B., Arastehfar, A., Camargo, C. H., Motta, A. L., et al. (2021) · Journal of Fungi · doi:10.3390/jof7040259 · Cited by 95
Roudbary, M., Kumar, S., Kumar, A., Černáková, L., Nikoomanesh, F., & Rodrigues, C. F. (2021) · Journal of Fungi · doi:10.3390/jof7090720 · Cited by 95 · cited 1×
“11 Pulmonary Aspergillosis (CAPA) [35-37], mucormycosis [38-40] and Candida 352 infections [41, 42] (see reviews in [43, 44]).”
BackgroundChoi, Y. J., Kim, Y.-J., Yong, D., Byun, J.-H., Kim, T. S., Chang, Y. S., Choi, M. J., Byeon, S. A., Won, E. J., Kim, S. H., et al. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2409.180625 · Cited by 88 · cited 3×
“In 98 recent years, however, a steady increase of resistance has been observed 99 worldwide, mostly in the context of nosocomial outbreaks [11-20].”
BackgroundSingh, A. K., Singh, P. K., de Groot, T., Kumar, A., Mathur, P., Tarai, B., Sachdeva, N., Upadhyaya, G., Sarma, S., Meis, J. F. G. M., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz029 · Cited by 87 · cited 4×
“In addition, we found that one of the 240 resistant isolates harbored the K143R mutation in ERG11 gene, which has 241 been detected in azole non-susceptible strains causing monoclonal outbreaks 242 in India [26] and also in combination with the Y132F mutation [11].”
BackgroundInfluentialInvasive Aspergillosis as an Under-recognized Superinfection in COVID-19
Thompson III, G. R., Cornely, O. A., Pappas, P. G., Patterson, T. F., Hoenigl, M., Jenks, J. D., Clancy, C. J., & Nguyen, M. H. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa242 · Cited by 85 · cited 2×
“8 • OFID • Trevijano-Contador et al diseases, such as COVID-associated pulmonary aspergillosis (CAPA) [36–38], mucormycosis [39–41], and Candida infections [42, 43] (see reviews in [44, 45]).”
BackgroundFekkar, A., Blaize, M., Bouglé, A., Normand, A.-C., Raoelina, A., Kornblum, D., Kamus, L., Piarroux, R., & Imbert, S. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02036-20 · Cited by 85 · cited 2×
“In 98 recent years, however, a steady increase of resistance has been observed 99 worldwide, mostly in the context of nosocomial outbreaks [11-20].”
BackgroundArastehfar, A., Hilmioğlu-Polat, S., Daneshnia, F., Pan, W., Hafez, A., Fang, W., Liao, W., Şahbudak-Bal, Z., Metin, D. Y., Júnior, J. N. D. A., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.676177 · Cited by 83 · cited 2×
“Another strain harbored the G458S mutation, which has been related to azole resistance in Candida parapsilosis [4, 28].”
BackgroundMartini, C., Torelli, R., de Groot, T., De Carolis, E., Morandotti, G. A., De Angelis, G., Posteraro, B., Meis, J. F., & Sanguinetti, M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00232 · Cited by 82 · cited 3×
“In 98 recent years, however, a steady increase of resistance has been observed 99 worldwide, mostly in the context of nosocomial outbreaks [11-20].”
BackgroundSegrelles‐Calvo, G., Araújo, G. R. D. S., Pastor, E. L., Carrillo, J., Hernández‐Hernández, M., Rey, L., Melean, N. R., Escribano, I., Antón, E. G., Zamarro, C., et al. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106619 · Cited by 81
Changing epidemiology of candidaemia: Increase in fluconazole‐resistant Candida parapsilosis
Mesini, A., Mikulska, M., Giacobbe, D. R., Puente, F. D., Gandolfo, N., Codda, G., Orsi, A., Tassinari, F., Beltramini, S., Marchese, A. E., et al. (2020) · Mycoses · doi:10.1111/myc.13050 · Cited by 77 · cited 2×
“In 98 recent years, however, a steady increase of resistance has been observed 99 worldwide, mostly in the context of nosocomial outbreaks [11-20].”
BackgroundGrau, S., Hernández, S., Echeverría-Esnal, D., Almendral, A., Ferrer, R., Cáceres, E. L., Horcajada, J. P., & (VINCat-PROA), O. B. O. T. C. I. C. A. S. P. (2021) · Antibiotics · doi:10.3390/antibiotics10080943 · Cited by 74 · cited 2×
“Among azoles, an increase in the use of echinocandins and voriconazole has been reported [46], which might have favored the selection of fluconazole and voriconazole-resistant C.”
BackgroundZiccardi, M., Souza, L. O. P., Gandra, R. M., Galdino, A. C. M., Rossit, A. R. B., Nunes, A. P. F., Ribeiro, M. A., Branquinha, M. H., & dos Santos, A. L. S. (2015) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2015.08.003 · Cited by 68 · cited 1×
“parapsilosis is a rare phenomenon, 97 being less than 5% of isolates in different epidemiological studies [2, 7-10].”
BackgroundAlcoceba, E., Gómez, A., Lara-Esbrí, P., Oliver, A., Beltrán, A. F., Ayestarán, I., Muñoz, P., Escribano, P., & Guinea, J. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.02.025 · Cited by 66 · cited 15×
“In our case, this idea is supported by the fact that we identified that some of the resistant clones were already detected in samples from 2019 (ie, Bellvitge Hospital) and also in some strains present in our collection from 2019 from the same geographical region.”
BackgroundSelf-citationCorzo-León, D., Peacock, M., Rodríguez‐Zulueta, P., Salazar-Tamayo, G., & MacCallum, D. M. (2020) · Medical Mycology · doi:10.1093/mmy/myaa098 · Cited by 64
Thomaz, D. Y., Del Negro, G. M. B., Ribeiro, L. B., da Silva, M., Carvalho, G. O. M. H., Camargo, C. H., de Almeida, J. N., Motta, A. L., Siciliano, R. F., Sejas, O. N. E., et al. (2022) · Journal of Fungi · doi:10.3390/jof8020100 · Cited by 64 · cited 2×
“In 98 recent years, however, a steady increase of resistance has been observed 99 worldwide, mostly in the context of nosocomial outbreaks [11-20].”
BackgroundRisk Factors of Candida parapsilosis Catheter-Related Bloodstream Infection
Yamin, D. H., Husin, A., & Harun, A. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.631865 · Cited by 63 · cited 1×
“associated to a higher risk of infection [5, 6].”
BackgroundSevere COVID-19 and healthcare-associated infections on the ICU: time to remember the basics?
Sturdy, A., Basarab, M., Cotter, M., Hager, K. M., Shakespeare, D. T., Shah, N., Randall, P., Spray, D. C., & Arnold, A. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.06.027 · Cited by 60 · cited 1×
“Third, during the pandemic 335 there were changes in personal protective equipment use and the same gloves 336 could have been used between patients [32, 33].”
BackgroundRamos, A., Pintos-Pascual, I., Guinea, J., Gutiérrez‐Villanueva, A., Abreu, E. V. G., Díaz-García, J., Asensio, Á., Iranzo, R., Sánchez‐Romero, I., Muñoz‐Algarra, M., et al. (2022) · Journal of Fungi · doi:10.3390/jof8050451 · Cited by 59 · cited 2×
“parapsilosis strains has been found in the outbreaks from Son Espases Universitary Hospital (Balearic Islands) and Puerta de Hierro Universitary Hospital (Madrid) [29, 47].”
BackgroundSelf-citationCultrera, R., Barozzi, A., Libanore, M., Marangoni, E., Pora, R., Quarta, B., Spadaro, S., Ragazzi, R., Marra, A. R., Segala, D., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18084358 · Cited by 58 · cited 1×
“parapsilosis infections in COVID-19 350 patients [34], but also other fungal diseases, such as Covid Associated 351 All rights reserved.”
BackgroundDiab-Elschahawi, M., Forstner, C., Hagen, F., Meis, J. F., Lassnig, A. M., Presterl, E., & Klaassen, C. H. W. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01179-12 · Cited by 57 · cited 2×
“Three trinucleotide repeat markers and 1 hexanucleotide repeat marker described by Diab-Elschahawi [25] were independently amplified by PCR.”
MethodInfluentialDíaz-García, J., Gómez, A., Alcalá, L., Reigadas, E., Sánchez‐Carrillo, C., Pérez‐Ayala, A., de la Pedrosa, E. G., González‐Romo, F., Amador, P. M., Cuétara, M. S., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00710-22 · Cited by 55 · cited 10×
“The National Centre for Microbiology from Instituto de Salud Carlos III (CNM-ISCIII, Madrid, Spain) acts as a national reference center for clinically isolated fungi, providing services such as genotyping and confirmation of antifungal susceptibility profiles by the European Committee on Antimicrobial Susceptibility T…”
ResultSelf-citationDemirci‐Duarte, S., Arıkan-Akdağlı, S., & Gülmez, D. (2021) · Mycoses · doi:10.1111/myc.13296 · Cited by 43
Xisto, M. I. D. S., Caramalho, R. D. F., Rocha, D. A. S., Ferreira-Pereira, A., Sartori, B., Barreto-Bergter, E., Junqueira, M. L., Lass-Flörl, C., & Lackner, M. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw558 · Cited by 41
Sahu, R. K., Salem-Bekhit, M. M., Bhattacharjee, B., Almoshari, Y., Ikbal, A. M. A., Alshamrani, M., Bharali, A., Salawi, A., Widyowati, R., Alshammari, A., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10091079 · Cited by 38
Singh, K., Kumar, S., Shastri, S., Sudershan, A., & Mansotra, V. (2021) · Immunogenetics · doi:10.1007/s00251-021-01226-5 · Cited by 30 · cited 1×
“11 Pulmonary Aspergillosis (CAPA) [35-37], mucormycosis [38-40] and Candida 352 infections [41, 42] (see reviews in [43, 44]).”
BackgroundIncreasing morbidity and mortality of candidemia over one decade in a Swiss university hospital
Battistolo, J., Glampedakis, E., Damonti, L., Poissy, J., Grandbastien, B., Kalbermatter, L., Pagani, J., Eggimann, P., Bochud, P., Calandra, T., et al. (2021) · Mycoses · doi:10.1111/myc.13376 · Cited by 29 · cited 1×
“parapsilosis is a rare phenomenon, 97 being less than 5% of isolates in different epidemiological studies [2, 7-10].”
BackgroundFive probable factors responsible for the COVID-associated mucormycosis outbreak in India
Ravindra, K., & Ahlawat, A. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.057 · Cited by 28 · cited 1×
“11 Pulmonary Aspergillosis (CAPA) [35-37], mucormycosis [38-40] and Candida 352 infections [41, 42] (see reviews in [43, 44]).”
Iatta, R., Caggiano, G., Cuna, T., & Montagna, T. (2011) · Journal of Chemotherapy · doi:10.1179/joc.2011.23.2.92 · Cited by 22
Abelenda-Alonso, G., Puig‐Asensio, M., Jiménez‐Martínez, E., García-Lerma, E., Hornero, A., Gutiérrez, C., Torrecillas, M., Tebé, C., Pujol, M., & Carratalà, J. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.118 · Cited by 7 · cited 1×
“Moreover, during the pandemic, there were changes in personal protective equipment protocols, and the same gloves could have been used between patients [33, 34].”
Self-citation
Cited by
Daneshnia, F., de Almeida Júnior, J. N., Ilkit, M., Lombardi, L., Perry, A. M., Gao, M., Nobile, C. J., Egger, M., Perlin, D. S., Zhai, B., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00067-8 · Cited by 257
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
Giannella, M., Lanternier, F., Dellière, S., Groll, A. H., Mueller, N. J., Alastruey‐Izquierdo, A., & Slavin, M. A. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.08.006 · Cited by 106
Candida parapsilosis complex in the clinical setting
Govrins, M. A., & Lass‐Flörl, C. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00961-8 · Cited by 94
“Homozygous mutations cause higher minimal inhibitory concentrations (MICs) than heterozygous ones 150 ; usually, strains with the above-mentioned substitutions are susceptible to amphotericin B and echinocandins including ibrexafungerp.”
BackgroundFluconazole-resistant Candida parapsilosis: A new emerging threat in the fungi arena
Escribano, P., & Guinea, J. (2022) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2022.1010782 · Cited by 74
“…et al., 2021; Fekkar et al., 2021; Thomaz et al., 2021; Alcoceba et al., 2022, Diaz-Garcia et al., 2022a, Hare et al., 2022; Thomaz et al., 2022; Zaragoza et al., 2022) K143R** R S (Singh et al., 2019, Arastehfar et al., 2020a, Castanheira et al., 2020) G458S*** R R or I (Arastehfar et al.,…”
Self-citation
Metadata
- Authors
- Trevijano-Contador, N., Torres-Cano, A., Carballo-González, C., Puig-Asensio, M., Martín-Gómez, M. T., Jiménez-Martínez, E., Romero, D., Nuvials, F. X., Olmos-Arenas, R., Moretó-Castellsagué, M. C., Fernández-Delgado, L., Rodríguez-Sevilla, G., Aguilar-Sánchez, M.-M., Ayats-Ardite, J., Ardanuy-Tisaire, C., Sanchez-Romero, I., Muñoz-Algarra, M., Merino-Amador, P., González-Romo, F., Megías-Lobón, G., García-Campos, J. A., Mantecón-Vallejo, M. Á., Alcoceba, E., Escribano, P., Guinea, J., Durán-Valle, M. T., Fraile-Torres, A. M., Roiz-Mesones, M. P., Lara-Plaza, I., de Ayala, A. P., Simón-Sacristán, M., Collazos-Blanco, A., Nebreda-Mayoral, T., March-Roselló, G., Alcázar-Fuoli, L., & Zaragoza, O.
- Affiliations
- Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III. Carretera Majadahonda-Pozuelo , Madrid , Spain
- Instituto de Salud Carlos III (ES)
- Department of Infectious Diseases, Hospital Universitari de Bellvitge-Institut d´Investigació Biomèdica de Bellvitge (IDIBELL) , Barcelona , Spain
- Universitat Autònoma de Barcelona (ES)
- Department of Microbiology, Vall D'Hebron University Hospital, Universitat Autònoma de Barcelona , Barcelona , Spain
- Intensive Care Unit, Vall D'Hebron University Hospital, Universitat Autònoma de Barcelona , Barcelona , Spain
- Bellvitge University Hospital (ES)
- Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL , Barcelona , Spain
- Microbiology Department, Hospital Universitario Puerta de Hierro , Majadahonda, Madrid , Spain
- Microbiology Department, Hospital Universitario Clínico San Carlos , Madrid , Spain
- Department of Clinical Microbiology, Hospital Universitario de Burgos , Burgos, Castilla y León , Spain
- Hospital Universitario de Burgos (ES)
- Hospital Universitario Son Espases (ES)
- Hospital General Universitario Gregorio Marañón (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES)
- Microbiology and Parasitology Department, Hospital Universitario de Móstoles , Madrid , Spain
- Microbiology Department, Marqués de Valdecilla Universitary Hospital and Instituto de Investigación Valdecilla (IDIVAL), Santander, Cantabria, Spain
- Marqués de Valdecilla University Hospital (ES)
- Microbiology Unit, Universitary Hospital 12 de Octubre , Madrid , Spain
- Microbiology and Parasitology Department, Hospital Central de la Defensa Gómez Ulla , Madrid , Spain
- Hospital Clínico Universitario de Valladolid (ES)
- ORCID
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-11-01
- Volume
- 9
- Issue
- 11
- Pages
- ofac605-ofac605
- ISSN
- 2328-8957 (ISSN-L)
- PMC
- PMC9709632
- OpenAlex
- W4308458455
- Cited by
- 54
- References
- 47
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 18 · 2023: 12 · 2022: 2
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Open Forum Infectious Diseases (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by-nc-nd)
- Funders
- National Centre for Microbiology
- Instituto de Salud Carlos III
- Center for Biomedical Research (CB21/13/00105, CB21/13/00009, CB06/06/0037, CB06/06/0058)
- Fondo de Investigación (MPY 117/18, MPY 305/20)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida parapsilosis, fluconazole resistance, voriconazole resistance, azole resistance, candidemia, ERG11, molecular epidemiology, COVID-19 pandemic, antifungal susceptibility, Spain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.